var data={"title":"Iron dextran: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iron dextran: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6403?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iron-dextran-drug-information\" class=\"drug drug_general\">see &quot;Iron dextran: Drug information&quot;</a> and <a href=\"topic.htm?path=iron-dextran-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iron dextran: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708946\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Anaphylactic-type reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during iron dextran administration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Administer a test dose of iron dextran prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic iron dextran dose. During all iron dextran administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have followed the test dose of iron dextran injection. Fatal reactions have also occurred in situations in which the test dose was tolerated.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions to iron dextran.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Use iron dextran only in patients in whom clinical and laboratory investigations have established an iron-deficient state not amenable to oral iron therapy. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184543\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dexferrum [DSC];</li>\n      <li>Infed</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184544\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dexiron;</li>\n      <li>Infufer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020277\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Iron Salt, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Mineral, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443752\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dexferrum has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of salt one form for another (dextran vs sucrose) without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy. Iron dextran: 1 mL provides 50 mg elemental iron</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia of prematurity:</b> IV (Dexferrum, INFeD): Limited data available:  0.2 to 1 mg/kg/day (Friel 1995; Ohls 1997) or 20 mg/kg/week (Carnielli 1998) with epoetin alfa therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020308\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=iron-dextran-drug-information\" class=\"drug drug_general\">see &quot;Iron dextran: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dexferrum has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one salt form for another (dextran vs sucrose) without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy. Iron dextran: 1 mL provides 50 mg elemental iron. <b>Note:</b> Dosing presented as both mg and mL; use caution when ordering and dispensing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency anemia:</b> Infants &ge;4 months, Children, and Adolescents: IM (INFeD), IV (Dexferrum, INFeD):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Test dose:</i> Usual reported range: 10 to 25 mg (0.2 to 0.5 mL) administered 1 hour prior to starting iron dextran therapy (de la Cruz 2004; Hastings 2012; Reed 1981; Waraday 2004; Waraday 2014). The manufacturer suggests a fixed test dose of 25 mg (0.5 mL) however, lower doses and a weight-based approach may be preferable and some centers have used:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &lt;10 kg: 10 mg (0.2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 10 to 20 kg: 15 mg (0.3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;20 kg and Adolescents: 25 mg (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Total replacement dosage of iron dextran for iron deficiency anemia:</i> Calculate total volume of dose (iron dextran 50 mg/mL elemental iron); if total replacement dose is large, may consider dividing total dose and utilizing smaller incremental dosages not to exceed recommended maximum daily dosages for route.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose (mL) = 0.0442 (Hb<sub>n</sub> - Hb<sub>o</sub>)  x LBW  + (0.26 x LBW)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">LBW = lean body weight in kg. <b>Note:</b> For patients weighing  5 to 15 kg,  use actual body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hb<sub>n</sub> = desired hemoglobin (g/dL) = 12 g/dL if &le;15 kg or 14.8 g/dL if  &gt;15 kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hb<sub>o</sub> = measured hemoglobin (g/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maximum daily dosage:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV (Dexferrun, INFeD): 100 mg (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IM (INFeD):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants &lt;5 kg: 25 mg (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children 5 to 10 kg: 50 mg (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &gt;10 kg and Adolescents: 100 mg (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute blood loss; total iron replacement dosage:</b> Infants &ge;4 months, Children, and Adolescents: IM (INFeD), IV (Dexferrum, INFeD): <b>Note: </b> Assumption: 1 mL of normocytic, normochromic red cells = 1 mg elemental iron; Calculate total volume of dose (iron dextran 50 mg/mL elemental iron); if total replacement dose is large, may consider dividing total dose and utilizing smaller incremental dosages not to exceed recommended maximum daily dosages for route.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Replacement iron (mg) = Blood loss (mL) x hematocrit (expressed as a decimal fraction)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum daily dosage:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV (Dexferrum, INFeD): 100 mg (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM (INFeD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &lt;5 kg: 25 mg (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 5 to 10 kg: 50 mg (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;10 kg and Adolescents: 100 mg (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia of chronic renal failure:</b> IV: <b>Note:</b> Initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See Reference Range for target levels. There is insufficient evidence to recommend IV iron if ferritin level &gt;500 ng/mL (KDOQI 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on the 2000 KDOQI Anemia Guidelines (KDOQI 2001). More recent KDOQI guidelines and the KDIGO guidelines no longer provide specific dosing recommendations or preferred product for intravenous iron supplementation (KDOQI 2006; KDIGO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Predialysis or peritoneal dialysis:</i> Infants and Children: As a single dose repeated as often as clinically indicated:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;10 kg: 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 to 20 kg: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;20 kg: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hemodialysis:</i> Infants, Children, and Adolescents: Administer  during each dialysis for 10 doses:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;10 kg: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 to 20 kg: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;20 kg: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> A 0.5 mL test dose should be given prior to starting iron dextran therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron-deficiency anemia:</b> IM (INFeD), IV (Dexferrum, INFeD):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose (mL) = 0.0442 (desired Hgb - observed Hgb) x LBW + (0.26 x LBW)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired hemoglobin: Usually 14.8 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">LBW = Lean body weight in kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron replacement therapy for blood loss:</b> IM (INFeD), IV (Dexferrum, INFeD): Replacement iron (mg) = blood loss (mL) x Hct</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maximum daily dosage:</b> Manufacturer's labeling: <b>Note:</b> Replacement of larger estimated iron deficits may be achieved by serial administration of smaller incremental dosages. Daily dosages should be limited to 100 mg iron (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal Impairment:</b> Nondialyzable. There are no dosage adjustment provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic Impairment:</b> There are no dosage adjustment provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184523\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexferrum: 50 mg/mL (1 mL [DSC], 2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infed: 50 mg/mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184507\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963476\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=iron-dextran-drug-information\" class=\"drug drug_general\">see &quot;Iron dextran: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strength of iron dextran complex is expressed as elemental iron.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49263683\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dexferrum has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020312\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> A test dose should be administered on the first day of therapy; observe the patient for at least 1 hour for hypersensitivity reaction, then the remainder of the day&rsquo;s dose (dose minus the test dose) should be administered. Resuscitation equipment, medication, and trained personnel should be available. An uneventful test dose does not ensure an anaphylactic-type reaction will not occur during administration of the therapeutic dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Use Z-track technique for IM administration (deep into the upper outer quadrant of buttock); alternate buttocks with subsequent injections; administer test dose at same recommended site using the same technique.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Test dose: Infuse test dose over at least 30 seconds (INFeD) or 5 minutes (Dexferum); doses may be injected undiluted at a rate not to exceed 50 mg/minute; large or total replacement doses may be diluted and infused over 1 to 6 hours at a maximum rate of 50 mg/minute (Silverstein 2004) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184536\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020278\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of iron deficiency when oral iron administration is infeasible or ineffective (FDA approved in ages &ge;4 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184569\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dexferrum may be confused with Desferal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Iron dextran complex may be confused with ferumoxytol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184566\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse event risk is reported to be higher with the high-molecular-weight iron dextran formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, chest tightness, flushing, hypertension, hypotension, shock, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, disorientation, dizziness, headache, loss of consciousness, malaise, paresthesia, seizure, unresponsive to stimuli</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukocytosis, lymphadenopathy, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis (includes acute respiratory distress, circulatory shock)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (includes injection site cellulitis, inflammation at injection site, injection site phlebitis, local soreness/soreness at injection site, pain at injection site, swelling at injection site), local discoloration (at the site of intramuscular injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy (with intramuscular injection), arthralgia, arthritis, back pain, exacerbation of arthritis, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cyanosis, dyspnea, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, fibrosis (with intramuscular injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, neoplasm (at former injection site)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184531\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iron dextran or any component of the formulation; any anemia not associated with iron deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184511\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Delayed reaction: Delayed (1-2 days) infusion reaction (including arthralgia, back pain, chills, dizziness, and fever) may occur with large doses (eg, total dose infusion) of IV iron dextran; usually subsides within 3-4 days. May also occur (less commonly) with IM administration; subsiding within 3-7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity/anaphylactoid reactions: <b> [U.S. Boxed Warning]: Deaths associated with parenteral administration following anaphylactic-type reactions have been reported (use only where resuscitation equipment and personnel are available). A test dose should be administered to all patients prior to the first therapeutic dose. Anaphylactic and other hypersensitivity reactions have occurred even in patients who tolerated the test dose; observe for anaphylactic reactions during any iron dextran administration; fatalities have occurred with the test dose. A history of  drug allergy (including multiple drug allergies) and/or the concomitant use of an ACE inhibitor may increase the risk of anaphylactic-type reactions.</b> Adverse events (including life-threatening) associated with iron dextran usually occur more with the high-molecular-weight formulation (Dexferrum), compared to low-molecular-weight (INFeD) (Chertow, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies/asthma: Use with caution in patients with a significant history of allergies or asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cancer-associated anemia: In patients with cancer-related anemia (either due to cancer or chemotherapy-induced) requiring iron supplementation, the IV route is superior to oral therapy; IM administration is not recommended for parenteral iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; iron dextran may exacerbate cardiovascular complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with extreme caution in patients with serious hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal disease/impairment: In patients with chronic kidney disease (CKD) requiring iron supplementation, the IV route is preferred for hemodialysis patients; either oral iron or IV iron may be used for nondialysis and peritoneal dialysis CKD patients. Avoid use during acute kidney infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may exacerbate joint pain and swelling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. IV administration of iron dextran is often preferred over IM in the elderly secondary to a decreased muscle mass and the need for daily injections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Intramuscular iron dextran use in neonates may be associated with an increased incidence of gram-negative sepsis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Product interchangeability: Iron dextran products differ in chemical characteristics. The high-molecular-weight formulation (Dexferrum) and the low-molecular-weight formulation (INFeD) are not clinically interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: <b>[U.S. Boxed Warning]: Use only in patients where the iron deficient state is not amenable to oral iron therapy.</b> Discontinue oral iron prior to initiating parenteral iron therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carcinogenicity: Intramuscular injections of iron-carbohydrate complexes may have a risk of delayed injection site tumor development.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Iron overload: Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023251\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use parenteral iron products with caution in premature neonates; necrotizing enterocolitis has been reported; however, no causal relationship established. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299544\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184516\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13057&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184519\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6792945\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. It is not known if iron dextran (as iron dextran) crosses the placenta. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020316\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hematocrit, hemoglobin, reticulocyte count, serum ferritin, transferrin, percent transferrin saturation, TIBC; takes about 4 weeks of treatment to see increased serum iron and ferritin, and decreased TIBC. Serum iron concentrations should be drawn &ge;48 hours after last dose (due to rapid increase in values following administration); signs/symptoms of hypersensitivity reactions (during and &ge;30 minutes following infusion); hypotension (following infusion). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020304\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum iron: All ages: 22 to 184 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total iron binding capacity: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 100 to 400 mcg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children, Adolescents, and Adults: 250 to 400 mcg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferritin: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0 to 6 weeks:  0 to 400 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 weeks to 1 year: 10 to 95 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 9 years: 10 to 60 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 to 18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Male: 10 to 300 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Female: 10 to 70 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic kidney disease (CKD): Targets for iron therapy (KDOQI Guidelines 2007) to maintain Hgb 11 to 12 g/dL: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20% </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184510\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The released iron, from the plasma, eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184530\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks; serum ferritin peak: 7 to 9 days after IV dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 60% absorbed after 3 days; 90% after 1 to 3 weeks, the balance is slowly absorbed over months  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Uptake of iron by the reticuloendothelial system appears to be constant at about 10 to 20 mg/hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and feces via reticuloendothelial system</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323229\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Infed Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (2 mL): $31.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184533\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cosmofer (AE, AT, CN, DE, DK, ES, FI, GB, GR, ID, IE, JO, KR, KW, LT, LV, MY, NL, NO, PH, PL, PT, QA, SA, SE, TH, VE);</li>\n      <li>Desman (TW);</li>\n      <li>Driken (MX);</li>\n      <li>Fexibron (PE);</li>\n      <li>Fexiron (AR, PE, PY);</li>\n      <li>Imferon (AE, BH, CU, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TR, YE);</li>\n      <li>Intrafer (AR);</li>\n      <li>Supral (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    KDOQI. Anemia in Chronic Kidney Disease. Available at: <a>http://www.kidney.org/sites/default/files/docs/anemiainckd.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auerbach M, Ballard H, Trout JR, et al, &quot;Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial,&quot; <i>J Clin Oncol</i>, 2004, 22(7):1301-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/1505177/pubmed\" target=\"_blank\" id=\"1505177\">1505177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auerbach M, Witt D, and Toler W, &ldquo;Clinical Use of the Total Dose Intravenous Infusion of Iron Dextran,&rdquo; <i>J Lab Clin Med</i>, 1988, 111(5):566-70. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/3361236/pubmed\" target=\"_blank\" id=\"3361236\">3361236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benito RP and Guerrero TC, &ldquo;Response to a Single Intravenous Dose Versus Multiple Intramuscular Administration of Iron Dextran Complex: A Comparative Study,&rdquo; <i>Curr Ther Res Clin Exp</i>, 1973, 15(7):373-82. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/4198298/pubmed\" target=\"_blank\" id=\"4198298\">4198298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. <i>Nutrition</i>. 1995;11(2):163-168.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/7647482 /pubmed\" target=\"_blank\" id=\"7647482 \">7647482 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. <i>Arch Dis Child Fetal Neonatal Ed.</i> 1998;79(1):F44-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/9797624 /pubmed\" target=\"_blank\" id=\"9797624 \">9797624 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chertow GM, Mason PD, Vaage-Nilsen O, et al, &quot;Update on Adverse Drug Events Associated With Parenteral Iron,&quot; <i>Nephrol Dial Transplant</i>, 2006, 21(2):378-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/16286429/pubmed\" target=\"_blank\" id=\"16286429\">16286429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexferrum injection (iron dextran) [prescribing information]. Shirley, NY: American regent Inc; september 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friel JK, Andrews WL, Hall MS, et al, &quot;Intravenous Iron Administration to Very-Low-Birth-Weight Newborns Receiving Total and Partial Parenteral Nutrition,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 1995, 19(2):114-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/7609274/pubmed\" target=\"_blank\" id=\"7609274\">7609274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infed (iron dextran) [prescribing information]. Morristown NJ: Watson Pharma, Inc.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI. Anemia in Chronic Kidney Disease. Available at: <a>http://www.kidney.org/sites/default/files/docs/anemiainckd.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,&quot; <i>Am J Kidney Dis</i>, 2007, 50(3):471-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/17720528/pubmed\" target=\"_blank\" id=\"17720528\">17720528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI. Anemia in Chronic Kidney Disease. Available at: <a>http://www.kidney.org/sites/default/files/docs/anemiainckd.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/11229970 /pubmed\" target=\"_blank\" id=\"11229970 \">11229970 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. <i>J Pediatr</i>. 1997;131(5):661-665.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/9403642 /pubmed\" target=\"_blank\" id=\"9403642 \">9403642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Bertino JS Jr, Halpin TC Jr. Use of intravenous iron dextran injection in children receiving total parenteral nutrition.<i> Am J Dis Child</i>. 1981;135(9):829-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/6792906 /pubmed\" target=\"_blank\" id=\"6792906 \">6792906 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein SB, Rodgers GM. Parenteral iron therapy options. <i>Am J Hematol</i>. 2004;76(1):74-78. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/15114602 /pubmed\" target=\"_blank\" id=\"15114602 \">15114602 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Kausz A, Lerner G, et al. Iron therapy in the pediatric hemodialysis population. <i>Pediatr Nephrol</i>. 2004;19(6):655-661.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/15064942 /pubmed\" target=\"_blank\" id=\"15064942 \">15064942 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13057 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708946\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184543\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F184544\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1020277\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443752\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1020308\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184523\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F184507\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963476\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49263683\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1020312\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F184536\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1020278\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F184569\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184566\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184531\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184511\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023251\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299544\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184516\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184519\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6792945\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1020316\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1020304\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184510\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F184530\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323229\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F184533\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13057|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iron-dextran-drug-information\" class=\"drug drug_general\">Iron dextran: Drug information</a></li><li><a href=\"topic.htm?path=iron-dextran-patient-drug-information\" class=\"drug drug_patient\">Iron dextran: Patient drug information</a></li></ul></div></div>","javascript":null}